GeneDx Faces Securities Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 52 minutes ago
0mins
Source: Globenewswire
- Lawsuit Deadline: Investors must file lead plaintiff applications by August 3, 2026, to participate in the securities class action against GeneDx, concerning stock purchases made between April 16, 2025, and May 4, 2026, or risk losing their right to claim.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates and lowering its full-year guidance to $475-$490 million, indicating significant financial challenges ahead for the company.
- Stock Price Plunge: Following the disappointing financial report, GeneDx's stock price fell by $33.42, or 49.2%, which not only undermines investor confidence but may also lead to increased legal actions and regulatory scrutiny.
- Impairment Loss Disclosure: The company revealed a $31.2 million impairment loss from its acquisition of Fabric Genomics, which was expected to expand its market and revenue streams, but the current situation highlights a major strategic execution failure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 69.120
Low
155.00
Averages
171.43
High
200.00
Current: 69.120
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Genomic sequencing tests include whole genome sequencing, whole exome sequencing, prenatal genetic testing, targeted testing, pediatric neurology, general pediatrics, geneticists and genetic counsellors, and others. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by August 3, 2026, to participate in the securities class action against GeneDx, concerning stock purchases made between April 16, 2025, and May 4, 2026, or risk losing their right to claim.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates and lowering its full-year guidance to $475-$490 million, indicating significant financial challenges ahead for the company.
- Stock Price Plunge: Following the disappointing financial report, GeneDx's stock price fell by $33.42, or 49.2%, which not only undermines investor confidence but may also lead to increased legal actions and regulatory scrutiny.
- Impairment Loss Disclosure: The company revealed a $31.2 million impairment loss from its acquisition of Fabric Genomics, which was expected to expand its market and revenue streams, but the current situation highlights a major strategic execution failure.
See More
Hagens Berman Investigates GeneDx Securities Class Action
- Stock Collapse: GeneDx's stock plummeted 49% following its Q1 2026 earnings report on May 5, primarily due to a $31.2 million impairment charge, indicating a significant strategic misstep in its Fabric Genomics acquisition that severely undermined investor confidence.
- Financial Missteps: The company reported a tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing revenue targets by $2.5 million, highlighting a failure to deliver on promised synergies from the acquisition.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenues would be at least 20%, significantly lower than previous expectations, reflecting a challenging competitive landscape.
- Leadership Change: Following the stock price crash, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to prior management failures, which could impact future investor confidence.
See More
GeneDx Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must seek lead plaintiff status by August 3, 2026, highlighting investor concerns over potential legal risks associated with the company.
- Acquisition Impact: GeneDx announced the acquisition of Fabric Genomics in April 2025, but the lawsuit alleges that the company failed to disclose significant issues with Fabric Genomics that could negatively affect GeneDx's overall business, indicating potential risks in acquisition decisions.
- Declining Financial Performance: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69% and a reduction in projected earnings from $540-$555 million to $475-$490 million, leading to a stock price drop of over 49% following the announcement, reflecting market concerns about the company's financial health.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength and influence in securities fraud cases, which may significantly impact the outcome of the GeneDx lawsuit.
See More
GeneDx Faces Class Action Lawsuit, Shares Plunge 50%
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against GeneDx, alleging that the company made false statements between April 16, 2025, and May 4, 2026, misleading investors about its financial health and impacting shareholder rights.
- Financial Losses: GeneDx reported a Q1 2026 loss of -$0.28 per share and an operational loss of $57.5 million, while also lowering its 2026 revenue guidance by approximately $65 million, indicating a severe decline in profitability.
- Stock Price Plunge: Following the release of disappointing financial results, GeneDx's stock price fell from $67.93 on May 4, 2026, to $34.51, a drop of about 50%, reflecting market pessimism regarding the company's future prospects.
- Strategic Adjustments: The company recorded a $31.3 million write-down related to goodwill due to downward revisions in cash flow forecasts for its Fabric Genomics unit, highlighting significant challenges in its business strategy and market execution that could affect future competitiveness.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit filed by investors who allege that the company made significant misstatements regarding its acquisition of Fabric Genomics between April 16, 2025, and May 4, 2026, impacting investor decisions.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market and revenue streams through Fabric's software platform; however, the lawsuit claims that GeneDx failed to disclose critical viability issues with Fabric.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, revealing a $31.3 million impairment loss related to Fabric, which caused its stock price to plummet by over 49% following the announcement.
- Investor Action: Investors are encouraged to file for lead plaintiff status by August 3, 2026, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and operating on a contingency fee basis, urging investors to take action to protect their rights.
See More
GeneDx Faces Class Action Over Fabric Genomics Acquisition Misrepresentation
- Stock Price Collapse: GeneDx's stock plummeted 49% on May 5, 2026, following a disastrous Q1 earnings report that included a $31.2 million impairment charge, indicating a strategic failure in the Fabric Genomics acquisition that severely undermined investor confidence.
- Financial Performance Decline: The company reported a significant tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing revenue targets by $2.5 million, reflecting a lack of expected synergies and impacting future profitability.
- Leadership Changes: Following the stock crash, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to prior failures, which could affect corporate governance and strategic direction moving forward.
- Investor Lawsuit: Hagens Berman is initiating a securities class action against GeneDx, alleging misleading statements to investors, urging affected investors to contact the firm by August 3, highlighting the potential for increased legal risks that may further strain the company's financial situation.
See More
GeneDx Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by August 3, 2026, to participate in the securities class action against GeneDx, concerning stock purchases made between April 16, 2025, and May 4, 2026, or risk losing their right to claim.
- Declining Financial Performance: GeneDx reported a drop in adjusted gross margin from 74% to 69% in its Q1 2026 results, missing revenue estimates and lowering its full-year guidance to $475-$490 million, indicating significant financial challenges ahead for the company.
- Stock Price Plunge: Following the disappointing financial report, GeneDx's stock price fell by $33.42, or 49.2%, which not only undermines investor confidence but may also lead to increased legal actions and regulatory scrutiny.
- Impairment Loss Disclosure: The company revealed a $31.2 million impairment loss from its acquisition of Fabric Genomics, which was expected to expand its market and revenue streams, but the current situation highlights a major strategic execution failure.
See More
Hagens Berman Investigates GeneDx Securities Class Action
- Stock Collapse: GeneDx's stock plummeted 49% following its Q1 2026 earnings report on May 5, primarily due to a $31.2 million impairment charge, indicating a significant strategic misstep in its Fabric Genomics acquisition that severely undermined investor confidence.
- Financial Missteps: The company reported a tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing revenue targets by $2.5 million, highlighting a failure to deliver on promised synergies from the acquisition.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenues would be at least 20%, significantly lower than previous expectations, reflecting a challenging competitive landscape.
- Leadership Change: Following the stock price crash, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to prior management failures, which could impact future investor confidence.
See More
GeneDx Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must seek lead plaintiff status by August 3, 2026, highlighting investor concerns over potential legal risks associated with the company.
- Acquisition Impact: GeneDx announced the acquisition of Fabric Genomics in April 2025, but the lawsuit alleges that the company failed to disclose significant issues with Fabric Genomics that could negatively affect GeneDx's overall business, indicating potential risks in acquisition decisions.
- Declining Financial Performance: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69% and a reduction in projected earnings from $540-$555 million to $475-$490 million, leading to a stock price drop of over 49% following the announcement, reflecting market concerns about the company's financial health.
- Legal Firm Background: Robbins Geller Rudman & Dowd LLP, a leading securities litigation firm, has recovered $8.4 billion for investors over the past five years, showcasing its strength and influence in securities fraud cases, which may significantly impact the outcome of the GeneDx lawsuit.
See More
GeneDx Faces Class Action Lawsuit, Shares Plunge 50%
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against GeneDx, alleging that the company made false statements between April 16, 2025, and May 4, 2026, misleading investors about its financial health and impacting shareholder rights.
- Financial Losses: GeneDx reported a Q1 2026 loss of -$0.28 per share and an operational loss of $57.5 million, while also lowering its 2026 revenue guidance by approximately $65 million, indicating a severe decline in profitability.
- Stock Price Plunge: Following the release of disappointing financial results, GeneDx's stock price fell from $67.93 on May 4, 2026, to $34.51, a drop of about 50%, reflecting market pessimism regarding the company's future prospects.
- Strategic Adjustments: The company recorded a $31.3 million write-down related to goodwill due to downward revisions in cash flow forecasts for its Fabric Genomics unit, highlighting significant challenges in its business strategy and market execution that could affect future competitiveness.
See More
GeneDx Holdings Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. (NASDAQ: WGS) is facing a securities fraud class action lawsuit filed by investors who allege that the company made significant misstatements regarding its acquisition of Fabric Genomics between April 16, 2025, and May 4, 2026, impacting investor decisions.
- Acquisition Details: The company announced an agreement to acquire Fabric Genomics for up to $51 million, with $33 million in cash upfront, aiming to expand its market and revenue streams through Fabric's software platform; however, the lawsuit claims that GeneDx failed to disclose critical viability issues with Fabric.
- Financial Impact: On May 4, 2026, GeneDx reported a drop in adjusted gross margin and lowered earnings projections, revealing a $31.3 million impairment loss related to Fabric, which caused its stock price to plummet by over 49% following the announcement.
- Investor Action: Investors are encouraged to file for lead plaintiff status by August 3, 2026, with Kessler Topaz Meltzer & Check, LLP offering free case evaluations and operating on a contingency fee basis, urging investors to take action to protect their rights.
See More
GeneDx Faces Class Action Over Fabric Genomics Acquisition Misrepresentation
- Stock Price Collapse: GeneDx's stock plummeted 49% on May 5, 2026, following a disastrous Q1 earnings report that included a $31.2 million impairment charge, indicating a strategic failure in the Fabric Genomics acquisition that severely undermined investor confidence.
- Financial Performance Decline: The company reported a significant tenfold increase in net loss compared to the previous year, with the Fabric Genomics unit missing revenue targets by $2.5 million, reflecting a lack of expected synergies and impacting future profitability.
- Leadership Changes: Following the stock crash, GeneDx appointed Mark Gardner as the new president, and Hagens Berman is investigating whether this leadership change is related to prior failures, which could affect corporate governance and strategic direction moving forward.
- Investor Lawsuit: Hagens Berman is initiating a securities class action against GeneDx, alleging misleading statements to investors, urging affected investors to contact the firm by August 3, highlighting the potential for increased legal risks that may further strain the company's financial situation.
See More
